Genetic profile may predict best response to weight-loss drug Wegovy

Certain genes may identify patients with obesity who are most likely to respond strongly to Novo Nordisk's (NOVOb.CO), opens new tab weight-loss drug Wegovy, researchers reported on Monday.
The study, released at the Digestive Disease Week meeting in Washington, found a 95% likelihood that patients with this genetic profile would be strong responders to the treatment.